title: Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders.
abstract: Endocannabinoids and their receptors, mainly the CB(1) receptor type, function as a retrograde signaling system in many synapses within the CNS, particularly in GABAergic and glutamatergic synapses. They also play a modulatory function on dopamine (DA) transmission, although CB(1) receptors do not appear to be located in dopaminergic terminals, at least in the major brain regions receiving dopaminergic innervation, e.g., the caudate-putamen and the nucleus accumbens/prefrontal cortex. Therefore, the effects of cannabinoids on DA transmission and DA-related behaviors are generally indirect and exerted through the modulation of GABA and glutamate inputs received by dopaminergic neurons. Recent evidence suggest, however, that certain eicosanoid-derived cannabinoids may directly activate TRPV(1) receptors, which have been found in some dopaminergic pathways, thus allowing a direct regulation of DA function. Through this direct mechanism or through indirect mechanisms involving GABA or glutamate neurons, cannabinoids may interact with DA transmission in the CNS and this has an important influence in various DA-related neurobiological processes (e.g., control of movement, motivation/reward) and, particularly, on different pathologies affecting these processes like basal ganglia disorders, schizophrenia, and drug addiction. The present review will address the current literature supporting these cannabinoid-DA interactions, with emphasis in aspects dealing with the neurochemical, physiological, and pharmacological/therapeutic bases of these interactions.
authors.affiliation: Departamento de Bioquímica y Biología Molecular and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Universidad Complutense, Madrid, Spain. jjfr@med.ucm.es <jjfr@med.ucm.es>
authors.forename: Javier
authors.initials: J
authors.lastname: Fernández-Ruiz
authors.forename: Mariluz
authors.initials: M
authors.lastname: Hernández
authors.forename: José A
authors.initials: JA
authors.lastname: Ramos
mesh_terms: D000818:Animals; D002186:Cannabinoids / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D002540:Cerebral Cortex / Q000378:metabolism; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D008032:Limbic System / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
chemical_list: D002186:Cannabinoids; D004298:Dopamine
references.citation: Eur J Neurosci. 2001 Dec;14(11):1827-32
references.pmid: 11860478
references.citation: Brain Res. 2002 Sep 6;948(1-2):155-8
references.pmid: 12383968
references.citation: Neurosci Lett. 2008 Jun 13;438(1):10-3
references.pmid: 18457923
references.citation: AAPS J. 2009 Mar;11(1):39-44
references.pmid: 19184452
references.citation: Neurobiol Learn Mem. 2009 Oct;92(3):391-9
references.pmid: 19450698
references.citation: Eur Neuropsychopharmacol. 2009 Mar;19(3):196-204
references.pmid: 19116182
references.citation: Behav Brain Res. 2001 Jan 8;118(1):61-5
references.pmid: 11163634
references.citation: J Pharmacol Exp Ther. 2007 Oct;323(1):318-26
references.pmid: 17630359
references.citation: Neurobiol Dis. 2009 Oct;36(1):70-80
references.pmid: 19591935
references.citation: Neuroscience. 2000;99(4):661-7
references.pmid: 10974429
references.citation: Br J Pharmacol. 2003 Feb;138(4):544-53
references.pmid: 12598408
references.citation: Braz J Med Biol Res. 2006 Apr;39(4):421-9
references.pmid: 16612464
references.citation: Eur J Pharmacol. 1999 Nov 3;383(3):R1-2
references.pmid: 10594337
references.citation: Neurochem Res. 2001 Sep;26(8-9):1015-21
references.pmid: 11699929
references.citation: Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3655-60
references.pmid: 10725386
references.citation: Psychopharmacology (Berl). 2003 Jul;168(1-2):164-169
references.pmid: 12669182
references.citation: Neurobiol Learn Mem. 2004 Mar;81(2):144-9
references.pmid: 14990234
references.citation: Psychiatry Res. 2001 Oct 1;107(3):173-7
references.pmid: 11566433
references.citation: Brain Res. 2006 Feb 16;1073-1074:209-19
references.pmid: 16412990
references.citation: Brain Res Bull. 2003 Jul 15;61(2):125-8
references.pmid: 12831997
references.citation: Neurosci Lett. 2008 Jan 24;431(1):6-11
references.pmid: 18069125
references.citation: Mol Psychiatry. 2004 Oct;9(10):916-31
references.pmid: 15289816
references.citation: J Neurochem. 2003 Mar;84(5):1097-109
references.pmid: 12603833
references.citation: Handb Exp Pharmacol. 2005;(168):117-45
references.pmid: 16596773
references.citation: Brain Res. 2004 May 8;1007(1-2):152-9
references.pmid: 15064146
references.citation: Clin Neuropharmacol. 2004 May-Jun;27(3):108-10
references.pmid: 15190231
references.citation: J Neurophysiol. 2001 Jan;85(1):72-83
references.pmid: 11152707
references.citation: Br J Pharmacol. 2004 Sep;143(2):227-34
references.pmid: 15313883
references.citation: Behav Pharmacol. 2002 Sep;13(5-6):451-63
references.pmid: 12394421
references.citation: J Neurosci. 2005 Mar 16;25(11):2874-84
references.pmid: 15772347
references.citation: J Neurosci. 2006 Aug 16;26(33):8531-6
references.pmid: 16914679
references.citation: Neuroscience. 1998 Mar;83(2):393-411
references.pmid: 9460749
references.citation: Synapse. 2004 Sep 1;53(3):159-67
references.pmid: 15236348
references.citation: Eur J Neurosci. 2003 Sep;18(6):1607-14
references.pmid: 14511339
references.citation: Prog Retin Eye Res. 2008 Sep;27(5):501-26
references.pmid: 18725316
references.citation: Nat Med. 2001 Oct;7(10):1151-4
references.pmid: 11590440
references.citation: Curr Opin Pharmacol. 2003 Feb;3(1):54-61
references.pmid: 12550742
references.citation: Handb Exp Pharmacol. 2005;(168):445-77
references.pmid: 16596784
references.citation: Eur J Pharmacol. 1999 Jul 2;376(1-2):23-6
references.pmid: 10440085
references.citation: Eur J Neurosci. 2002 Jun;15(12):2057-61
references.pmid: 12099913
references.citation: Eur J Neurosci. 2001 Jul;14(1):96-102
references.pmid: 11488953
references.citation: J Pharmacol Exp Ther. 2003 Jul;306(1):93-102
references.pmid: 12660305
references.citation: Pharmacol Biochem Behav. 2005 Jun;81(2):387-95
references.pmid: 15935455
references.citation: Neuroscience. 2002;109(3):451-60
references.pmid: 11823058
references.citation: Eur J Pharmacol. 2008 Jan 14;578(2-3):137-41
references.pmid: 17931621
references.citation: Lipids Health Dis. 2003 Aug 19;2:5
references.pmid: 12969514
references.citation: Ann Neurol. 2008 Dec;64 Suppl 2:S30-46
references.pmid: 19127584
references.citation: Trends Endocrinol Metab. 2007 Jan-Feb;18(1):27-37
references.pmid: 17141520
references.citation: Dialogues Clin Neurosci. 2007;9(4):413-30
references.pmid: 18286801
references.citation: Neuropsychopharmacology. 2007 Oct;32(10):2098-107
references.pmid: 17299506
references.citation: J Clin Psychiatry. 2003 Apr;64(4):459-65
references.pmid: 12716250
references.citation: J Neural Transm Suppl. 2009;(73):269-75
references.pmid: 20411785
references.citation: Neuropsychopharmacology. 2007 Feb;32(2):298-308
references.pmid: 16760924
references.citation: Eur J Pharmacol. 1999 Jan 22;365(2-3):133-42
references.pmid: 9988095
references.citation: Neurology. 2001 Dec 11;57(11):2108-11
references.pmid: 11739835
references.citation: Trends Neurosci. 2000 Jan;23(1):14-20
references.pmid: 10631784
references.citation: Brain Res. 1997 Jul 18;763(1):63-8
references.pmid: 9272829
references.citation: Life Sci. 1999;65(6-7):703-13
references.pmid: 10462071
references.citation: Expert Opin Pharmacother. 2003 Oct;4(10):1717-25
references.pmid: 14521482
references.citation: Synapse. 2002 Apr;44(1):23-35
references.pmid: 11842443
references.citation: Mov Disord. 2002 Jan;17(1):145-9
references.pmid: 11835452
references.citation: Neurosci Biobehav Rev. 2006;30(5):680-95
references.pmid: 16574226
references.citation: J Neurochem. 1999 Sep;73(3):1084-9
references.pmid: 10461898
references.citation: Brain Res. 2002 Nov 1;954(1):73-81
references.pmid: 12393235
references.citation: J Neurosci. 2007 Apr 4;27(14):3663-76
references.pmid: 17409230
references.citation: Mov Disord. 2004 Aug;19(8):990-1
references.pmid: 15300675
references.citation: Brain Res. 1991 May 3;547(2):267-74
references.pmid: 1909204
references.citation: J Pharmacol Exp Ther. 2009 Mar;328(3):822-8
references.pmid: 19106171
references.citation: Brain Res. 2000 Feb 28;857(1-2):56-65
references.pmid: 10700552
references.citation: Neurosci Biobehav Rev. 2006;30(2):215-38
references.pmid: 16099045
references.citation: Eur J Pharmacol. 2003 Nov 7;480(1-3):133-50
references.pmid: 14623357
references.citation: Behav Brain Res. 2009 Nov 5;203(2):304-7
references.pmid: 19414037
references.citation: Eur J Neurosci. 2003 Apr;17(8):1723-6
references.pmid: 12752390
references.citation: Ann Neurol. 2005 May;57(5):777-9
references.pmid: 15852389
references.citation: Curr Pharm Des. 2008;14(23):2317-25
references.pmid: 18781982
references.citation: Br J Pharmacol. 2009 Apr;156(7):1029-40
references.pmid: 19220290
references.citation: J Neurosci. 2008 Dec 24;28(52):14018-30
references.pmid: 19109485
references.citation: Physiol Rev. 2009 Jan;89(1):309-80
references.pmid: 19126760
references.citation: Neurobiol Aging. 2011 Apr;32(4):631-45
references.pmid: 19419794
references.citation: Annu Rev Physiol. 2009;71:283-306
references.pmid: 19575681
references.citation: Acta Psychiatr Scand. 1984 Feb;69(2):162-74
references.pmid: 6142585
references.citation: Biol Psychiatry. 2006 Mar 15;59(6):508-15
references.pmid: 16199010
references.citation: Arch Gen Psychiatry. 2008 Jul;65(7):772-84
references.pmid: 18606950
references.citation: Pharmacol Biochem Behav. 2005 Jun;81(2):300-18
references.pmid: 15919107
references.citation: CNS Neurol Disord Drug Targets. 2009 Dec;8(6):432-9
references.pmid: 19839934
references.citation: Pharmacol Ther. 2007 Apr;114(1):13-33
references.pmid: 17349697
references.citation: Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):287-99
references.pmid: 12052043
references.citation: Pharmacopsychiatry. 2002 Mar;35(2):57-61
references.pmid: 11951146
references.citation: Eur J Pharmacol. 2001 Jan 26;412(2):R3-5
references.pmid: 11165232
references.citation: J Neurosci. 2003 Apr 15;23(8):3136-44
references.pmid: 12716921
references.citation: Prog Neurobiol. 2002 May;67(1):53-83
references.pmid: 12126656
references.citation: Trends Pharmacol Sci. 2001 Nov;22(11):565-72
references.pmid: 11698100
references.citation: Addict Biol. 2003 Jun;8(2):159-66
references.pmid: 12850774
references.citation: Eur J Neurosci. 1998 Sep;10(9):2825-30
references.pmid: 9758152
references.citation: Addict Biol. 2008 Jun;13(2):147-59
references.pmid: 18482430
references.citation: J Neurosci. 2007 Jan 24;27(4):791-5
references.pmid: 17251418
references.citation: Neuropharmacology. 2008 Feb;54(2):438-44
references.pmid: 18054052
references.citation: J Neurochem. 1993 Nov;61(5):1705-12
references.pmid: 7901331
references.citation: Neurochem Int. 2009 Jun;54(7):452-7
references.pmid: 19428788
references.citation: Nat Rev Drug Discov. 2008 May;7(5):438-55
references.pmid: 18446159
references.citation: J Pharmacol Exp Ther. 2005 Mar;312(3):875-83
references.pmid: 15525797
references.citation: Handb Exp Pharmacol. 2005;(168):479-507
references.pmid: 16596785
references.citation: Pharmacol Biochem Behav. 2005 Jun;81(2):263-84
references.pmid: 15936806
references.citation: Biochem Biophys Res Commun. 1999 Mar 16;256(2):377-80
references.pmid: 10079192
references.citation: Curr Opin Pharmacol. 2007 Dec;7(6):575-82
references.pmid: 17904903
references.citation: Eur J Pharmacol. 2007 May 7;562(1-2):82-91
references.pmid: 17336288
references.citation: J Neurochem. 2003 Feb;84(4):698-704
references.pmid: 12562514
references.citation: Am J Med Genet. 2001 Dec 8;105(8):749-52
references.pmid: 11803524
references.citation: Br J Pharmacol. 2008 May;154(2):369-83
references.pmid: 18414385
references.citation: Neuropsychopharmacology. 2004 Nov;29(11):2108-14
references.pmid: 15354183
references.citation: Neurobiol Dis. 2005 Jun-Jul;19(1-2):96-107
references.pmid: 15837565
references.citation: Prostaglandins Leukot Essent Fatty Acids. 2009 Oct;81(4):291-301
references.pmid: 19570666
references.citation: Physiol Rev. 2003 Jul;83(3):1017-66
references.pmid: 12843414
references.citation: Nature. 2007 Feb 8;445(7128):643-7
references.pmid: 17287809
references.citation: Neuropharmacology. 2002 Oct;43(5):857-67
references.pmid: 12384171
references.citation: Neuropharmacology. 2005 Jun;48(8):1105-16
references.pmid: 15878779
references.citation: CNS Neurol Disord Drug Targets. 2009 Dec;8(6):403-21
references.pmid: 19839937
references.citation: J Neurosci. 2001 Jan 1;21(1):109-16
references.pmid: 11150326
references.citation: Neuropharmacology. 2001 Jun;40(7):918-26
references.pmid: 11378162
references.citation: Exp Neurol. 2007 Nov;208(1):110-9
references.pmid: 17900568
references.citation: Neuropsychopharmacology. 2003 Jun;28(6):1160-7
references.pmid: 12637958
references.citation: Expert Rev Neurother. 2008 Jul;8(7):1037-48
references.pmid: 18590475
references.citation: Curr Opin Investig Drugs. 2009 Apr;10(4):305-10
references.pmid: 19337950
references.citation: Exp Brain Res. 2006 Jul;172(4):556-60
references.pmid: 16710682
references.citation: Int Rev Psychiatry. 2009 Apr;21(2):163-71
references.pmid: 19367510
references.citation: Neurotox Res. 2008 Oct;14(2-3):169-83
references.pmid: 19073424
references.citation: Psychopharmacology (Berl). 2001 Jun;156(1):79-85
references.pmid: 11465637
references.citation: Eur J Neurosci. 2002 Jun;15(11):1795-802
references.pmid: 12081659
references.citation: Am J Psychiatry. 2004 Jun;161(6):975-84
references.pmid: 15169685
references.citation: Neuropsychopharmacology. 2009 Feb;34(3):759-66
references.pmid: 18754005
references.citation: Neuropharmacology. 2009 Mar;56(3):676-83
references.pmid: 19101577
references.citation: Alcohol Clin Exp Res. 2001 Feb;25(2):277-82
references.pmid: 11236843
references.citation: Nat Neurosci. 1999 Apr;2(4):358-63
references.pmid: 10204543
references.citation: Mov Disord. 2008;23 Suppl 3:S534-47
references.pmid: 18781680
references.citation: Psychopharmacology (Berl). 2009 May;204(1):1-11
references.pmid: 19099297
references.citation: J Clin Psychopharmacol. 2008 Jun;28(3):317-24
references.pmid: 18480689
references.citation: Neurosci Lett. 2007 Jun 29;421(3):270-4
references.pmid: 17574742
references.citation: Curr Psychiatry Rep. 2005 Oct;7(5):344-51
references.pmid: 16216152
references.citation: J Neurosci. 2008 Oct 15;28(42):10496-508
references.pmid: 18923026
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):355-60
references.pmid: 14751433
references.citation: Mol Neurobiol. 2007 Aug;36(1):102-12
references.pmid: 17952655
references.citation: J Neurosci. 2008 Dec 17;28(51):13985-94
references.pmid: 19091987
references.citation: Drug Alcohol Depend. 2002 Mar 1;66(1):77-84
references.pmid: 11850139
references.citation: Mol Psychiatry. 2003 May;8(5):466-7
references.pmid: 12808424
references.citation: Neuroscience. 1992;48(3):655-68
references.pmid: 1376455
references.citation: J Neurosci. 2004 Jan 7;24(1):53-62
references.pmid: 14715937
references.citation: J Neurosci. 1991 Feb;11(2):563-83
references.pmid: 1992016
references.citation: Neuroreport. 1999 Jun 3;10(8):1665-9
references.pmid: 10501554
references.citation: Neuropsychopharmacology. 2008 Jun;33(7):1667-79
references.pmid: 17957223
references.citation: Mol Psychiatry. 2002;7(5):515-8
references.pmid: 12082570
references.citation: Neuropharmacology. 2008 May;54(6):976-88
references.pmid: 18371990
references.citation: Brain. 2003 Jun;126(Pt 6):1252-70
references.pmid: 12764049
references.citation: Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):301-7
references.pmid: 12052044
references.citation: Neuropharmacology. 2003 Apr;44(5):633-41
references.pmid: 12668049
references.citation: J Neural Transm (Vienna). 2007;114(8):1055-63
references.pmid: 17370106
references.citation: World Psychiatry. 2008;7(2):68-71
references.pmid: 18560513
references.citation: Neurotox Res. 2008 Oct;14(2-3):105-12
references.pmid: 19073418
references.citation: Neurology. 2004 Oct 12;63(7):1245-50
references.pmid: 15477546
references.citation: FASEB J. 2000 Jul;14(10):1432-8
references.pmid: 10877836
references.citation: Cell Mol Life Sci. 2006 Jul;63(14):1597-613
references.pmid: 16699809
references.citation: J Neurochem. 2010 Mar;112(6):1454-64
references.pmid: 20050977
references.citation: Int Rev Psychiatry. 2009 Apr;21(2):113-21
references.pmid: 19367505
references.citation: Handb Exp Pharmacol. 2005;(168):643-56
references.pmid: 16596791
references.citation: Int Rev Psychiatry. 2009 Apr;21(2):134-42
references.pmid: 19367507
references.citation: Mov Disord. 2004 Sep;19(9):1102-6
references.pmid: 15372606
references.citation: Eur J Pharmacol. 1996 Jan 11;295(2-3):163-8
references.pmid: 8720580
references.citation: Eur Arch Psychiatry Clin Neurosci. 2006 Oct;256(7):437-41
references.pmid: 16788767
references.citation: Neuropharmacology. 2008 Apr;54(5):815-23
references.pmid: 18262573
references.citation: Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8394-9
references.pmid: 12060782
references.citation: Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10269-73
references.pmid: 9707636
references.citation: Neuropharmacology. 2009;56 Suppl 1:226-34
references.pmid: 18691604
references.citation: Science. 1997 Jun 27;276(5321):2048-50
references.pmid: 9197269
references.citation: Int Rev Neurobiol. 2007;78:289-326
references.pmid: 17349865
references.citation: Eur J Neurosci. 2009 Jun;29(11):2177-86
references.pmid: 19490092
references.citation: Synapse. 2003 Jul;49(1):61-6
references.pmid: 12710016
references.citation: Expert Opin Ther Targets. 2006 Apr;10(2):203-10
references.pmid: 16548770
references.citation: J Neurochem. 2003 May;85(4):1018-25
references.pmid: 12716433
references.citation: Br J Pharmacol. 2005 Sep;146(2):167-9
references.pmid: 16025140
references.citation: Eur J Pharmacol. 2002 May 17;443(1-3):95-7
references.pmid: 12044797
references.citation: J Neurol Neurosurg Psychiatry. 1990 May;53(5):436
references.pmid: 2351975
references.citation: Schizophr Bull. 2008 Nov;34(6):1111-21
references.pmid: 18723841
references.citation: Neuroscience. 2001;103(1):9-15
references.pmid: 11311783
references.citation: Br J Pharmacol. 2001 Apr;132(8):1809-16
references.pmid: 11309253
references.citation: Neurosci Lett. 1998 May 1;246(3):169-72
references.pmid: 9792619
references.citation: Neurobiol Dis. 2005 Apr;18(3):591-601
references.pmid: 15755685
references.citation: Pharmacol Biochem Behav. 1981 Nov;15(5):779-83
references.pmid: 6273940
references.citation: Eur J Pharmacol. 2001 May 25;420(2-3):123-31
references.pmid: 11408034
references.citation: J Neurosci. 2005 Sep 14;25(37):8432-8
references.pmid: 16162925
references.citation: Psychiatry Res. 2006 Oct 30;147(2-3):249-56
references.pmid: 16919917
references.citation: Br J Pharmacol. 2007 Nov;152(5):671-5
references.pmid: 17704826
references.citation: Brain Res. 2007 Feb 23;1134(1):162-70
references.pmid: 17196181
references.citation: Neuroimage. 2009 Oct 15;48(1):186-90
references.pmid: 19539765
references.citation: J Neurosci. 2002 Aug 15;22(16):6900-7
references.pmid: 12177188
references.citation: Pharmacol Res. 2009 Aug;60(2):85-92
references.pmid: 19428268
references.citation: Mov Disord. 2007 Jul 30;22(10):1379-1389
references.pmid: 17427940
references.citation: Handb Exp Pharmacol. 2008;(184):435-77
references.pmid: 18064422
references.citation: Curr Opin Psychiatry. 2007 May;20(3):228-34
references.pmid: 17415074
references.citation: Trends Neurosci. 2006 Apr;29(4):225-32
references.pmid: 16483675
references.citation: Mol Cell Endocrinol. 2008 Apr 16;286(1-2 Suppl 1):S97-S107
references.pmid: 18372102
references.citation: Drug News Perspect. 2008 Apr;21(3):149-57
references.pmid: 18560613